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The novel coronavirus disease (COVID-19) vaccines may help control the current pandemic but would 
require immunization levels that would achieve herd immunity. This study aimed to quantify current 
COVID-19 vaccine acceptance rates, as well as characterize the determinants, enablers and barriers to 
vaccine acceptability across the globe by synthesizing published evidence. 
Methods: 
A systematic review and meta-analysis of studies was performed on studies assessing the acceptability 
of a COVID-19 vaccine published between November 1st, 2019, and November 30th, 2020. PubMed, 
Embase and Cochrane central were searched for eligible studies. Data extracted from retained studies 
was analyzed using STATA statistical software. A quantitative and narrative synthesis was produced. 
Results: 
A total of 35 eligible articles (38 studies) involving a total of 70,997 participants across 7 regions and 35 
countries were included. All studies were cross-sectional survey designs. The pooled vaccine acceptance 
rate across 32 studies was 71% (95% CI: 66 – 76%, p2= 99.4%, range: 29-97%). The pooled vaccine 
acceptance rate of parents for their children across 4 studies was 52% (95% CI: 37-67%, p2= 99.1%). 
Vaccine uptake was significantly higher among males (N=13 studies), older age groups (N=7), and 
healthcare providers (N=2). Enablers of vaccine uptake included perceived individual susceptibility to 
COVID-19 infection (N=11), prior influenza vaccination (N=7) and high vaccine effectiveness (N=6). The 
most common barriers to vaccine uptake were general negative attitudes towards vaccines/vaccine 
hesitancy (N=8), concerns over vaccine safety and efficacy (N=6), vaccine side effects (N=5), and 
misinformation or conspiracy beliefs around the experimental COVID-19 vaccines (N=2). 
Conclusions: 
There is a good acceptance of COVID-19 vaccines globally despite wide variations across countries. 
Public health campaigns may benefit from capitalising on identified enablers and dispelling important 
barriers with regards to vaccine safety. 
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Since the start of the coronavirus disease (COVID-19) pandemic in December 2019, there 
have been more than 70 million reported cases and more than a million and a half deaths due to 
infection with the SARS-CoV-2 virus.1 Despite social distancing measures, self-isolation 
following exposure, and intermittent lockdowns2,3, most countries are currently experiencing 
additional  waves of infections1. Vaccination appears to be a viable option to help control the 
pandemic.4 Significant progress has been made worldwide in the development of vaccines for 
COVID-19 with the recent rollout of mRNA vaccines by Pfizer & BioNTech (BNT162b2) and by 
Moderna (mRNA-1273), both with efficacies above 90%.5–8 
Vaccines can only be effective to halt a pandemic if taken by enough of the population to 
produce herd immunity in order to stop its further spread.9,10 Challenges to vaccination campaigns 
include affordability of the vaccine, willingness to pay for the vaccine11, maintenance of the 
vaccine supply and cold chains, distribution of the vaccine worldwide to the most hard-to-reach 
areas, and very importantly, the acceptability of these vaccines by the general population. 
Acceptability is particularly challenging in the current era given rapidly circulating vaccine 
misinformation campaigns through social and media communication channels.12 The World 
Health Organization cites “vaccine hesitancy” as one of the top ten threats to global health.13  
Levels of vaccine hesitancy vary across both geographical and socio-demographic population 
characteristics and are believed to be high enough to significantly affect acceptable levels of 
population immunity.14–18 Failing to adequately prepare the general population and key 
stakeholders on the importance of these COVID-19 vaccines could therefore result in poor vaccine 
acceptability, as has been shown with other novel vaccines19, and was seen in the recent H1N1 
pandemic.20 Exploring current vaccine acceptance rates, determinants of acceptability across 
populations and specific at-risk subgroups is essential in informing policy on the multi-faceted and 
targeted approaches required to ensure adequate vaccine acceptance and coverage to achieve herd 
immunity. This study aimed to synthesize published evidence on the determinants of COVID-19 
vaccine acceptance worldwide, through a systematic review and meta-analysis. The study 
objectives were to: assess the current acceptance rates of a potential COVID-19 vaccine; determine 
socio-demographic and clinical characteristics in study populations that affect vaccine acceptance; 
and determine potential enablers and barriers to vaccine uptake. 
Methods 
This review was registered with the international prospective register of systematic reviews 
(PROSPERO registration number: CRD42020224096). The Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) 2009 guidelines21 were used to report this 
protocol (see Supplementary file 1 for more details). 
Search strategy, screening process and selection criteria 
This was a systematic review of studies that quantitatively assessed the COVID-19 vaccine 
acceptance rates and explored enablers and barriers to vaccine uptake. The search strategy used is 
presented in Supplementary file 2. The search strategy was developed by the authors with the 
assistance of an experienced medical librarian. The keywords COVID-19, Coronavirus, SARS-
CoV-2 and their synonyms were combined with the keywords ‘vaccine’, ‘vaccination’, 
‘immunization’, as well as the keywords ‘acceptability’, ‘receptivity’, ‘enablers’, ‘barriers’ and 
their respective synonyms using the Boolean operator ‘AND’ in the search strategy. The search 
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was run by the principal investigator (CAD). All searches were limited to articles in English. 
Databases searched included PubMed, Embase and Cochrane Central. Specialist searches for grey 
literature, public calls for literature, organizational websites or stakeholder contacts were not 
performed for this review. 
 
Articles from the initial search were saved on Zotero Version 5.0.93 reference management 
software from which duplicates of articles were removed by the principal investigator (CAD). Two 
reviewers (CAD and BMK) then independently screened the titles and abstracts of the remaining 
articles to exclude articles outside of the scope of this review. Both reviewers then independently 
reviewed the full text of the retained articles according to the study selection criteria to identify 
eligible studies. There were no disagreements between both reviewers at each stage of the study 
selection process. The reference lists of eligible studies were also reviewed to identify more 
eligible studies. 
 
The following studies were included: 
1. Peer-reviewed studies published in English between November 1st, 2019, and November 
30th, 2020; 
2. Population: Studies on patients of all ages, both healthcare providers and non-healthcare 
providers; 
3. Intervention: Studies on COVID-19 vaccine acceptance; 
4. Outcomes: Studies reporting either COVID-19 vaccine acceptance rates, or determinants, 
enablers and barriers to vaccine uptake; 
5. Study design: observational studies, including cross-sectional studies and surveys. 
 
The following studies were excluded: 
1. Population: Studies on participants who had been involved in COVID-19 vaccine trials; 
2. Intervention: Studies focused on participants’ willingness to participate in COVID-19 
vaccine trials, rather than actual participant intent to receive the COVID-19 vaccine; 
studies reporting uptake to other vaccines similar to the COVID-19 vaccine such as the 
influenza vaccine; 
3. Outcomes: Studies not reporting at least one of either vaccine acceptance rate, 
determinants, enablers or barriers; studies reporting exclusively on participants’ 
willingness to pay for a COVID-19 vaccine rather than their intent to get vaccinated; 
studies reporting combined COVID-19 preventive health behavior including vaccination 
rather than vaccination as an individual preventive measure; 
4. Other: Pre-prints, conference abstracts, editorials and letters not providing adequate 
information on the studies and outcomes of interest, bulletins, opinion papers, media 
reports. 
Study validity assessment, data extraction and synthesis 
Two independent reviewers assessed the quality and risk of bias of the eligible studies, 
comparing the reports to a hypothetical cross-sectional survey that mirrored the population 
demographics, wrote clear and unambiguous survey questions and collected all potential known 
confounding variables for vaccine uptake. The study quality were graded as poor, fair or good 
using the Study Quality Assessment Tools of the National Health Institute/National Heart, Lung 
and Blood Institute (NHI/NHLBI)22 (see Supplementary file 3 for more details). 
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Metadata including the first author and publication year, and data on study methods and 
outcomes of interest were extracted from the selected studies unto a Microsoft Excel® extraction 
sheet. This data included study location (continent/region and country), study design, socio-
demographic and clinical characteristics of study participants, study duration, vaccine acceptance 
rates, measures of effect/association (risk ratios, odds ratios, hazard ratios, relative risks, 
percentage change, and their respective confidence intervals) of the determinants/predictors of 
vaccine acceptance or hesitancy and reported enablers and barriers to vaccine acceptance. For 
studies not directly providing vaccine acceptance rates, the vaccine uptake rate was calculated as 
a proportion of the number of participants who mentioned they would accept a COVID-19 vaccine 
if available, to the total number of participants who answered that question. Vaccine acceptance 
was reported as ‘yes’ or ‘no’ to the question ‘do you intend to take the COVID-19 vaccine?’ For 
studies that only reported the number of participants who answered ‘yes’, we assumed the 
remaining participants to have responded with a ‘no’ to vaccination. Conversely, for studies 
reporting vaccine hesitancy as ‘no’ only, we assumed the remaining participants to have responded 
with a ‘yes’ to vaccination. For studies that reported vaccine acceptance as ‘yes’, ‘no’, and ‘not 
sure’, these answers were extracted and presented as such. For studies that reported the vaccine 
acceptance on a Likert scale such as ‘definitely yes’, ‘likely/probably yes’, ‘definitely no’, and 
‘likely/probably no’, these were grouped into ‘yes’ and ‘no’ options only, with ‘definitely yes’ and 
‘likely/probably yes’ answers grouped into the option ‘yes’ and the ‘definitely no’ and 
‘likely/probably no’ answers grouped into the option ‘no’. All extracted data was double-checked 
for errors by a second independent investigator. Data extracted was exported to STATA version 
14.2 (STATA Corp, College Station, TX) for analysis. 
Narrative synthesis of the study characteristics, as well as the socio-demographic and 
clinical characteristics of the participants in the various studies was done, complemented by tables 
with descriptive statistics. Random effects meta-analyses were performed after Freeman-Tukey 
Double Arcsine Transformation23 to derive pooled estimates for the vaccine acceptance rate. 
Pooled estimates of the odds ratios for the effect of participants’ sex on vaccine acceptance were 
also derived. Random effect models were used to account for between-study heterogeneity.  
Heterogeneity was assessed and presented using the Cochrane’s Q test and the I2 test statistic. 
These findings were presented on forest plots and summarized in tables. Publication bias through 
small-study effect assessment was determined both statistically (Egger’s test) and graphically 
(funnel plot). For qualitative data on vaccine acceptance enablers and barriers extracted from the 
selected studies, a thematic content analysis approach was adopted for data analysis and synthesis. 
An initial coding framework was developed on Microsoft Excel® 2016 after identifying the main 
recurrent themes on enablers and barriers to vaccine uptake from the studies. This initial coding 
framework was then expanded to incorporate sub-themes that emerged as more studies were 
reviewed and analyzed in depth. Findings were also presented and summarised in tables. 
Results 
A PRISMA flow chart for the study selection process is presented on Figure 1 and a list of 
studies excluded following full text review is presented in Supplementary file 4. 
Study characteristics 
A total of 35 eligible articles all published in 202014–16,24–55, and involving 38 studies were 
included in the review. The study characteristics are summarized on Table 1. This involved a total 
of 70,997 participants across 7 regions (Africa, Asia, Europe, Middle East, North America, South 
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America, Oceania) in 35 countries. Four of the studies were multinational.14,35,42,48 All studies were 
cross-sectional surveys and 34 were entirely online (Table 1). Seven studies were of good quality, 
23 of fair quality and 6 of poor quality (see Supplementary file 3 for more details). The average 
male participation across the studies was 39%. Participants’ ages ranged from 18 to 93 years 
(N=23), with age groups between 18 to 54 years being the most prevalent across studies (N=16) 
and age groups above 55 years being the most prevalent age group among participants in 4 
studies.30,33,38,47 Among the 11 studies that reported the ethnicity of the participants, the mean 
percentage of participants of Asian, Black, Hispanic, White and other ethnicities were 4%, 13%, 
15%, 71%, and 5% respectively. An average of 82.4% of the participants resided in urban settings 
(N=8) and 71.2 % had an educational level beyond high school (N=21). Trust in the government 
and their handling of the current pandemic were reported in 2 studies at 75.4%50 and 47.9%.41  
Vaccine acceptance rate 
The vaccine acceptance rate ranged from 28%39 to 97%50, with an overall combined 
acceptance rate of 71% (95% CI: 66 – 76%, p<0.001 across 32 studies with significant between-
study heterogeneity; I2= 99.4%, p<0.001) (Figure 2). 
Conversely, combined vaccine hesitancy among participants who responded with a ‘no’ to the 
intent to vaccinate question across 33 studies was 15% (95% CI: 11 – 19%, p<0.001, I2 = 99.4%, 
p<0.001, range: 2-72%) (Figure 3). 
The combined proportion of participants who answered ‘not sure’ to if they would take the 
COVID-19 vaccine across 20 studies that reported this was 20% (95% CI: 16 – 23%, p<0.001) 
(Figure 4). There was both graphical evidence (Figure 5) and statistical evidence (Egger’s test, 
p=0.003) of small-study effect. 
The combined vaccine acceptance rate by parents for children in four studies was at 52% 
(95% CI: 37-67% p<0.001, I2=99.1%, p<0.001) (Figure 6). Conversely, the combined vaccine 
hesitancy rate of parents for their children was 27% (95% CI: 9-49%, p<0.001, I2 = 99.62%, 
p<0.001) (Figure 6). Lastly, the combined proportion of parents who answered ‘not sure’ to if they 
would give the vaccine to their children in two studies who offered this was 41% (95% CI: 38- 
43%, p<0.001) (Figure 6). 
A single study reported a vaccine acceptance rate of 61% if vaccination was required by 
the participants’ employers.40 
On meta-regression, study sample size was categorized into studies with less than 1000 
participants and those with 1000 or more participants; disease prevalence per region categorized 
into high (North America, South America, Europe) and low (Africa, Middle East, Asia, Oceania); 
and study quality categorized into good and fair or poor quality. There was no evidence that the 
between-study heterogeneity was due to any of these study characteristics (Supplementary file 5). 
Socio-demographic determinants of vaccine uptake and hesitancy 
The factors significantly associated with increased vaccine uptake included: male sex 
(N=14)15,16,29,32,34,37,39,42,44,48,49,52,53,55, with a pooled adjusted OR of 1.60 (95% CI: 1.38 - 1.84, 
p<0.001, N=9, I2 = 59.2%, p=0.012). Similarly, Reiter et al. reported  female sex  as a barrier to 
vaccine uptake.16 Older age increased uptake (N=7), with the lowest uptake for the age group 30-
49 years, and increasing uptake for ages above 45 and 55 years respectively.15,25,29,34,42,48,51 
Additional positive associations included higher educational attainment (N=5)15,30,33,37,49, being 
married (N=2)25,52, higher household income (N=2)16,27, and healthcare providers compared to 
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non-healthcare providers (N=2).29,38 The socio-demographic determinants of vaccine uptake and 
hesitancy are summarised on Table 2. 
Enablers of vaccine uptake 
COVID-19 infection-related factors that favoured vaccine acceptance included perceived 
individual susceptibility to COVID-19 infection (N=11)16,29,32,34,36–38,49,51,52,55, fear of acquiring the 
infection (N=3)25,29,34, perceived severity of the disease and general positive attitude towards the 
disease (N=4)16,36,39,54, and desire to protect self and others (N=2).27,54 
Vaccination-related factors that favoured vaccine uptake included current or prior influenza 
vaccination in the preceding year (N=7)15,32–34,51–53, belief in the efficacy of the vaccine and high 
(>90%) vaccine effectiveness (N=6)31,37,38,40,45,52, positive attitudes towards the vaccine 
(N=5)36,43,51,55, lower vaccine side effects (N=4)40,45,51,55 and longer duration of the protection 
offered by the vaccine (N=2).31,50 
Trust-related factors included trust in the health care system or following a doctor’s 
recommendation (N= 4)16,25,27,52 and trust in scientific research (N=2).43,48 
Other factors associated with vaccine uptake included health engagement, possession of 
health insurance, urban settings and more time spent on vaccine development. The enablers of 
vaccine across the included studies are summarised on Table 3. 
Barriers to vaccine uptake 
Vaccination-related factors reported as barriers to vaccine uptake included general negative 
attitudes towards vaccines or vaccine hesitancy (N=8)29,33,34,37,42,50,52,55, safety and efficacy of the 
vaccine (N=6)27,33,42,45,52,54, side effects of the vaccine (N=5)31,33,37,42,45, rushed development of the 
vaccines (N=3)27,33,37, cost of the vaccine (N=2)31,55 and fear of injections or higher frequency of 
injections (N=2).31,55 
Misinformation-related factors included general misinformation together with participants’ 
susceptibility to misinformation/misconceptions (N=4)30,33,48,54, conspiracy beliefs especially 
about an experimental vaccine (N=2)42,47 and inadequate health literacy (N=1).30 
Other reported factors significantly associated with vaccine hesitancy included having children 
(N=2)32,49, FDA authorisation of the vaccine for emergency use, possible shortages of the vaccine, 
country of origin of the vaccine and content of the vaccine27, specific populations subgroups such 
as people who already had the COVID-19 infection27, pregnant women and people with allergies.42 
The most frequently reported barriers to vaccine uptake across the studies included are summarized 
on Table 4. 
Discussion 
This review identified a good general acceptance of COVID vaccination worldwide, 
although a wide variability across countries was identified. It also summarizes enablers and 
barriers to vaccine uptake across 38 studies. This information is particularly relevant to policy 
makers across several countries currently planning on the rollout of the COVID-19 vaccines and 
prioritization of at-risk groups, as well as ensuring adequate vaccine coverage to ensure attainment 
of herd immunity. These findings also complement those of a recent systematic review on the 
receptivity of the COVID-19 vaccines which included syndicated surveys and peer-reviewed 
studies.56 
Lower vaccine rates were noted in countries of the least affected inhabited continent, 
Africa, while high acceptance rates were noted in Europe (Supplementary file 6) which is one of 
5
Akem Dimala et al.: Acceptability of the COVID-19 Vaccine: A Systematic Review and Meta-analysis
Published by RocScholar, 2021
 
the most affected continents.1 Nevertheless, a coordinated global response with regards to vaccine 
implementation is required, as disease transmission in a country with low vaccine 
acceptance/coverage could result in new outbreaks of the disease in the unvaccinated populations 
in countries with high vaccine coverage due to the easy transmissibility of the infection across 
borders. As reported in this review, a non-negligible proportion of the population is still undecided 
about their intent to get vaccinated. This should be an important subgroup of the population that 
governments and health systems and public health campaigns could capitalise on to edge closer to 
herd immunity. This would involve putting more emphasis on the identified enablers to vaccine 
uptake and minimising the impact of identified barriers to vaccine uptake on this population group. 
The health belief model underpins the responses of individuals to health interventions, as 
individuals’ responses to health interventions in such situations is largely based on their perceived 
risk of the disease and benefits of the proposed interventions.57 The pandemic nature of COVID-
19 infection has made it a global concern, directly or indirectly affecting individuals at all corners 
of the globe. This is reflected in the high vaccine acceptance rates in several countries and the 
perceived individual susceptibility to COVID-19 infection as one of the main determinants of 
vaccine acceptance.16,29,32,34,36–38,49,51,52,55 Other important motivators to vaccine uptake are the 
development of vaccines of high enough effectiveness31,40,55, with longer durations of 
protection.31,50 
Concerns about vaccine safety and fear of the vaccine side effects together with the record-
breaking vaccine development time underpin the hesitancy to accept the COVID-19 vaccine as 
noted in this review. These factors should be addressed by health authorities together with the 
scientific community through adequate communication58 and health education campaigns among 
others to reduce the important vaccine hesitancy rate as noted in this study and enhance vaccine 
uptake. Likewise, dispelling misinformation and conspiracy beliefs around the COVID-19 
vaccines are essential in order to observe greater vaccine uptake, especially in the context of 
inadequate health literacy, as these remain important barriers to vaccine uptake.30,30,33,42,47,48,54 
These misinformation and conspiracy beliefs are propagated by anti-vaccine movements mainly 
through online communication channels.59 Involving these movements in discussions have also 
been proposed to improve vaccine uptake.60 
Reinforcing known enablers of vaccine acceptance such as trust in the health system, health 
institutions, scientists and research altogether could turn out to be vital. This could be achieved 
with adequate community engagement. Inadequate community engagement is known to adversely 
affect the implementation of community-based interventions and clinical research61, including the 
introduction of novel vaccines.19 This could include appropriate stakeholder analysis and 
involvement to aid with engagement of population groups noted to be less likely to take the vaccine 
such as such as females33, ethnic minorities16,27,33, and non-healthcare providers among others.29,38 
Higher vaccine uptake rates were observed in healthcare providers probably due to a combination 
of their greater knowledge on the merits of vaccines and their increased exposure and susceptibility 
to infection. 
Contrary to the belief that people with children are more likely to get vaccinated to reduce 
their risk of getting infected and transmitting the disease to their household, having children was 
found to be a barrier to vaccine uptake.32,49 Also, a lower overall vaccine acceptance rate for 
children from their participating parents was observed, thought to be due to beliefs of lower disease 
transmission and disease severity among children.27 This pooled vaccine acceptance estimate was 
from four studies only, as such more studies are required to make stronger conclusions on vaccine 
uptake for children. 
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It is worth taking into consideration that the observed vaccine acceptance rate in this review 
could be lower than in actual populations. This is because most studies in the review were 
conducted through online surveys with an overall younger participant population with a known 
lower disease severity who are less likely to take the vaccine compared to older individuals who 
are at higher risk of severe infection.62,63 
The interpretation of the findings from this review should take into consideration a few 
limitations. The inclusion of studies exclusively published in English limits the generalizability of 
our findings to other settings, especially as COVID-19 disease is a pandemic affecting the entire 
globe at present. Also, important heterogeneity across the studies should be kept in mind while 
interpreting the pooled summary estimates from these studies with different study populations and 
methodological approaches, which implies that the variability between studies is due to study 
heterogeneity rather than chance. We therefore limited our meta-analysis to vaccine acceptance 
rate and proceeded with a narrative synthesis of the determinants of vaccine uptake given the 
expected between-study heterogeneity. Nonetheless, this review provides extensive evidence on 
the reception of COVID-19 vaccines across several countries and populations and could therefore 
be important in informing policy makers in several countries on important parameters to consider 
while establishing measures to optimize vaccine uptake in their respective settings. The fast-
evolving nature of the COVID-19 pandemic means the findings of this study may not necessarily 
represent the actual vaccine acceptance rates and trends in the future. All included studies were 
published before the data on safety and efficacy of the current vaccines were known. Therefore, 
the responses of the participants to vaccine acceptance could not have taken this information into 
account. As this data becomes widespread and as internet misinformation spreads, public 
perceptions could change in either direction depending on the presence and seriousness of the side 
effects reported.  
Conclusion 
There is an overall good acceptance of COVID-19 vaccines globally despite the wide 
variations across countries. It is unclear, however, if the current acceptance rates will be sufficient 
to achieve herd immunity. Capitalising on identified enablers of vaccine uptake such as the high 
effectiveness of the vaccines and dispelling important barriers such as misinformation and 
conspiracy beliefs around vaccine safety and efficacy is essential in enhancing vaccine uptake in 
at-risk subpopulations with ‘unsure’ vaccination intents. Breaking the chain of disease 
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Tables 
Table 1: Socio-demographic characteristics of participants in the studies included  








Abdelhafiz Egypt  in-person 
& online 
Convenience general  559  37.7  
Al-Mohaithef Saudi Arabia  online Snowball general  992  NR 
Barello Italy  online NR students  934  20.4  
Bell England  online NR parents & 
guardians  
1252  5.0 
Bertin 1 France  online NR general  409  26.1 
Bertin 2 France online NR general   
Detoc France  online NR general  3259  32.6 
Dodd Australia  online NR General 4362  NR  
Dong China  online NR general  1236  49.1 
Dror Israel  online NR general  1941  NR  
Fisher USA  online Multistage general  991  NR  
Gagneux-
Brunon  
France  in-person 
& online 
NR HCW 2047  26 
Goldman Multinational online Convenience parents & 
care givers  
1541  50 
Graffigna  Italy  online Random general  1004  NR  
Guidry USA  online NR general  788  49.1 
Harapan Indonesia  online NR general  1359  34.3  
Kabamba Congo  self-
administered 
NR HCW  613  50.9  
Lazarus Multinational† online Random general  13426  49.3  
Kreps USA  online NR general  1971  45.7  
Malik USA  online Snowball general  672  41.7 
Muqattash UAE online NR general  1109  27.9 
Neumann-
Bohme 
Multinational‡ online Random general  7664  NR  
Palamenghi Italy  online Convenience general  1004  NR  
Papagiannis Greece  online NR HCW 461  25.8  
Pogue  USA  online NR general  316  50.3 
Reiter USA  online Convenience general  2006  43.3 
Reuben Nigeria  online Snowball general  589  59.6 
Romer 1 USA  online NR general  1050  46.3 
Romer 2 USA  online NR general  840  47.7 
Roozenbeek Multinational* online NR general  5000  48.8 
Salali 1 UK  online NR general  1088  29.6 
Salali 2  Turkey  online NR general  3936  37.4 
Sarasty Ecuador  online NR general  972  61 
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Sherman UK  online NR general  1500  48.6  
Wang J China  online Stratified 
random 
general  2058  12.5 
Wang K China  online Stratified 
random 
HCW 806  45.8 
Williams   UK online NR general  527  43.1 
Wong China in-person 
& online 
NR general 1159 34 
Multinational - USA, Canada, Israel, Japan, Spain, Switzerland; Multinational† - Brazil, Canada, China, 
Ecuador, France, Germany, India, Italy, Mexico, Nigeria, Poland, Russia, Singapore, South Africa, 
Spain, Sweden, UK, USA; Multinational‡ - Denmark, France, Germany, Italy, Portugal, Netherland, 
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Table 2: Socio-demographic and clinical determinants of vaccine uptake and hesitancy 
Socio-demographics Studies Authors Estimates, 95%CI 
Vaccine acceptance (increase vaccine uptake) 
Sex 





Salali, Wang, Wang, 
Wong, 
Summary estimate 
OR: 1.60, 95% CI: 1.38 – 
1.84 
N=9, I2=59.2%, p=0.012 
Age 
Older age compared to 
younger age 







Asian compared to other 
ethnicities 
1 Malik NR 
White and Hispanic 
compared to Black 
1 Guidry NR, (p=0.001 and 
p<0.001) 
Marital status 




aOR: 1.79, 95%CI: 1.28-
2.50 





2 Malik, Guidry NR 
Occupation 
Healthcare workers 




OR: 1.53, 95% CI: 1.27 – 
1.85 
OR: 2.01; 95% CI: 1.01 – 
4.00 
Healthcare workers 
Doctors compared to nurses 




1.59, 95% CI: 1.03 - 2.44, 
and OR: 2.66, 95% CI: 
1.77 - 4.03 
Household Income 
Higher household income 




aOR: 0.35, 95%CI: 0.17 - 
0.73 
aRR: 1.07, 95% CI: 1.01 - 
1.14 
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aRR: 1.09, 95% CI: 1.02 - 
1.16 
Vaccine hesitancy (decrease vaccine uptake) 
Sex 
Female 1 Reiter aRR: 0.91, 95% CI: 0.87–
0.96 
Age 
Younger age compared to 
older age 
1 Fisher NR 
Middle age compared to 18-
34 year and >60 years age 
groups 
1 Palamenghi NR 
Ethnicity 
Black, Asian, Chinese, 
Mixed or Other ethnicities 
compared to White British  
1 Bell aOR: 2.7, 95%CI: 1.27–
5.87 
Black ethnicity compared to 
other ethnicities 
1 Fisher OR: 6.4, 95% CI: 3.2 - 13 





3 Dodd, Fisher, Salali NR 
Occupation 
Retired compared to civil 
servant 
1 Harapan NR 
aOR – adjusted odds ratio, aRR – adjusted risk ratio, CI – confidence interval, NR – measure of 
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Table 3: Enablers of Vaccine uptake 
Enablers  Studies Authors Estimates, 95%CI 
Covid-19 disease related factors 
Perceived individual risk of 
COVID-19 infection 









aOR: 1.510, 95% CI: 1.269 - 
1.851 
aOR: 2.48, 95% CI: 1.93 - 3.2  
aOR: 2.21, 95% CI: 1.07 - 
4.59  
aRR: 1.05, 95% CI: 1.01 - 
1.09  
aOR: 1.12, 95% CI: 1.04 - 1.2  
aOR:1.46, 95% CI: 1.04 - 
2.05  
aOR: 1.36, 95% CI 1.04 - 
1.79  
NR 
Fear of acquiring the 
infection 
3 Al-Mohaithef  
Detoc  
Gagneux-Brunon  
aOR: 2.13, 95% CI: 1.35 - 
3.85  
aOR: 2.445, 95% CI: 1.998 - 
2.991  
aOR: 4.69, 95% CI: 3.59-6.11  
Perceived severity and 
attitude towards the disease 
3 Kabamba  
Reiter  
Graffigna, Williams  
aOR: 11.49, 95% CI: 5.88 - 
22.46  
aRR: 1.08, 95% CI: 1.04 - 
1.11  
NR  
Protect self/others and health consequence to others  
Protect self/others and health 
consequence to others 
2 Bell, Williams  NR 
Vaccination-related factors 
Current or prior influenza 
vaccination 
7 Fisher  
Gagneux-Brunon  
Wang J  
Wang K  
Dror, Malik, Sherman  
RRR: 0.06, 95% CI: 0.03 - 
0.11  
aOR: 4.69, 95% CI: 3.59-6.11  
OR:1.90, 95% CI: 1.43–2.51  
OR: 2.03, 95%CI: 1.47–2.81  
NR 
Belief in vaccine 
efficacy/high effectiveness 
(>90%) 
6 Kreps  
Guidry  
Wang J  
Dong, Harapan, 
Pogue,   
coef: 0.16, 95% CI: 0.15 - 
0.18  
aRR: 1.46, 95% CI: 1.40 - 
1.52  
OR:1.56, 95% CI: 1.08–2.25)  
NR  
Positive attitude 






r = .618; p < .001  
OR = 2.51, 95% CI 1.19–5.26  
NR 
18




Lack or lower vaccine side 
effects 
4 Kreps  
Wong  
Pogue, Sherman 
coef: 0.07, 95% CI: 0.05 - 
0.08  
OR = 1.81, 95% CI 1.34–2.44  
NR 
Longer duration of protection 
by the vaccine 
2 Dong, Sarasty NR 
Trust-related factors 
Trust in the health 
system/doctor’s 
recommendation 
4 Al-Mohaithef  
Reiter  
Wang J  
Bell  
aOR: 1.533, 95% CI: 1.269 - 
1.851  
aRR: 1.73, 95% CI: 1.49 - 
2.02  
OR:2.32, 95% CI: 1.76–3.07  
NR 
Trust in scientific 
research/scientists 
2 Palamenghi  
Roozenbeek 
r = .373; p < .001  
OR = 1.73, 95% CI: 1.57–
1.91  
Other factors 
Urban setting 1 Fisher  (RRR 0.33, 95% CI: 0.18 - 
0.61) 
Health engagement  1 Graffigna NR 
More time spent on vaccine 
testing 
1 Pogue NR 
Having health insurance 2 Guidry, Reiter  NR 
aOR – adjusted odds ratio, aRR – adjusted risk ratio, CI – confidence interval, NR – measure of 
effect not reported, RRR – relative risk ratio 
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Table 4: Barriers to vaccine uptake 
Barriers  Studies Authors Estimates, 95%CI 
Vaccination-related factors 
General vaccine 
hesitancy or negative 
attitude towards vaccines 




Bohme, Fisher, Guidry, 
Wang J 
aOR: 0.275, 95% CI: 0.23 - 
0.329   
aOR: 0.37, 95% CI: 0.29 - 0.48 
NR, 52.5% 
NR 






NR, 45.45%  
NR  
NR, 76.43%  
NR, 15%  
NR, 2/83  
NR, 49%  






NR, p<0.001  
NR, 63.47%  
NR, 55%  
NR, 14/83 
Rushed development of 
the vaccine 
3 Guidry  
Fisher  
Bell  
NR, p<0.001  
NR, 1/83  
NR, 50% 
Vaccine cost 2 Dong  
Wong  
NR  
NR, 88.5%  
Fear of or higher 
frequency of injections 
2 Dong  
Guidry  
NR  










OR = 0.77, 95% CI: 0.72 - 
0.83  
NR, 11/83  





2 Romer  
Neumann-Bohme  




1 Dodd OR: 0.58, 95% CI: 0.46 - 0.73 
Other factors 
Having children 2 Dror  
Salali  
NR, p=0.013  
aOR: 0.82, 95% CI: 0.69 - 
0.96  
Perceived barriers 1 Guidry NR 
Possible vaccine shortage 1 Guidry  NR p=0.001   
MMR Harm  1 Romer  0.033, 95% CI: 0.072 - 0.003 
20




FDA emergency use 
authorisation  
1 Kreps  coef: -0.03, 95% CI: -0.04 - 
0.01 
vaccine originating from 
a non-US country 
1 Kreps  
Kreps  
China: -0.13, 95% CI: -0.15 to 
-0.11 
UK: −0.04, 95% CI: -0.06 to -
0.02) 
aOR – adjusted odds ratio, MMR – measles, mumps, rubella, CI – confidence interval, NR – 
measure of association not reported 
Figure Legend 
Figure 1: PRISMA Flow Chart for Study Selection 
Figure 2: Forest plot showing the pooled and individual vaccine acceptance rates to the 
SARS-CoV-2 across 32 studies. The dashed line on the Forest plot represents the overall pooled 
estimate. The grey squares and horizontal lines represent the vaccine acceptance rate of each 
study and their 95% confidence intervals. The size of the grey square represents the weight 
contributed by each study in the meta-analysis. The diamond represents the pooled vaccine 
acceptance rate and its 95% confidence intervals. 
Figure 3: Forest plot showing the pooled and individual vaccine hesitancy rates to the SARS-
CoV-2 across 33 studies. The dashed line on the Forest plot represents the overall pooled 
estimate. The grey squares and horizontal lines represent the vaccine acceptance rate of each 
study and their 95% confidence intervals. The size of the grey square represents the weight 
contributed by each study in the meta-analysis. The diamond represents the pooled vaccine 
acceptance rate and its 95% confidence intervals. 
Figure 4: Forest plot showing the pooled and individual rates of uncertainty to vaccination 
against the SARS-CoV-2 across 20 studies. The dashed line on the Forest plot represents the 
overall pooled estimate. The grey squares and horizontal lines represent the vaccine acceptance 
rate of each study and their 95% confidence intervals. The size of the grey square represents the 
weight contributed by each study in the meta-analysis. The diamond represents the pooled vaccine 
acceptance rate and its 95% confidence intervals. 
Figure 5: Funnel Plot for studies on Covid-19 vaccine acceptance rate 
The blue dots represent the studies, the solid vertical line represents the pooled estimate of the 
vaccine acceptance rate obtained from the meta-analysis, the dashed diagonal lines represent the 
95% confidence limits around the pooled estimate. 
Figure 6: Pooled Vaccine Acceptance rate among parents for their children 
The dashed line on the Forest plot represents the overall pooled estimate. The grey squares and 
horizontal lines represent the vaccine acceptance rate of each study and their 95% confidence 
intervals. The size of the grey square represents the weight contributed by each study in the meta-
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214 retrieved from databases search 
PubMed (179), Embase (19), Cochrane (16) 
 
211 records 
Title and abstract screened 
43 records  
Full text reviewed 




































2 studies added from the reference list of 
relevant studies 
170 excluded as out of scope 
8 excluded 
• 3 preprints 
• 1 letter to editor 
• 2 focused on vaccine clinical trials 
• 2 on willingness to pay 
3 duplicates excluded 
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Figure 3: Forest plot showing the pooled and individual vaccine hesitancy rates to the SARS-








Overall  (I^2 = 99.42%, p = 0.00)
Dong
Kabamba
Salali - study 2
Romer - study 2
Wong
Bertin - study 2
Reuben





































































































































0 .1 .2 .5 .8 1
24




Figure 4: Forest plot showing the pooled and individual rates of uncertainty to vaccination 
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Funnel plot with pseudo 95% confidence limits
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Figure 6: Pooled Vaccine Acceptance rate among parents for their children 
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Supplementary Files 
Supplementary file 1. Preferred Reporting Items for Systematic review and Meta-Analysis 
(PRISMA-P) 2009 checklist 
Section/topic  # Checklist item Page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis 
methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
3 
Objectives  4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
3 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 




6 Specify study characteristics (e.g., PICOS, length of follow-up) 
and report characteristics (e.g., years considered, language, 




7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
21 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, 





10 Describe method of data extraction from reports (e.g., piloted 
forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
5&6 
28




Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and 
simplifications made.  
6 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in 




13 State the principal summary measures (e.g., risk ratio, difference 




14 Describe the methods of handling data and combining results of 
studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
6 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 




16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  
N/A 
RESULTS  
Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each stage, 




18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and provide 
the citations.  
7&18 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any 








20 For all outcomes considered (benefits or harms), present, for each 
study: (a) simple summary data for each intervention group (b) 





21 Present results of each meta-analysis done, including confidence 
intervals and measures of consistency.  
8 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies 




23 Give results of additional analyses, if done (e.g., sensitivity or 
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24 Summarize the main findings including the strength of evidence 
for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
10-12 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), 
and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
11&1
2 
Conclusions  26 Provide a general interpretation of the results in the context of 
other evidence, and implications for future research.  
12 
FUNDING  
Funding  27 Describe sources of funding for the systematic review and other 














1 "COVID-19" [Supplementary Concept] OR 2019-nCoV[tiab] OR 2019nCoV[tiab] 
OR COVID-19[tiab] OR SARS-CoV-2[tiab] OR “novel coronavirus”[tiab] 
AND  
2 COVID-19 vaccine" [Supplementary Concept] OR vaccin*[tiab] OR 
immuniz*[tiab] OR BNT162[tiab] OR BNT162b2[tiab] OR mRNA-1273[tiab] OR 
“mRNA 1273”[tiab] OR ChAdOx1[tiab] OR Pfizer OR BioNTech OR Moderna OR 
AstraZeneca 
AND  
3 Patient Acceptance of Health Care"[Mesh] OR accepta*[tiab] OR receptivity[tiab] 
OR "Attitude"[Mesh] OR attitude[tiab] OR willingness[tiab] 
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Supplementary file 3. Quality Assessment of the included studies 
Criteria Abdelhafiz Al-
Mohaithef 




Detoc Dodd Dong 
1. Was the research question or objective in this paper 
clearly stated? 
Yes Yes Yes Yes Yes Yes Yes Yes No 
2. Was the study population clearly specified and 
defined? 
Yes Yes Yes Yes No Yes No No Yes 
3. Was the participation rate of eligible persons at least 
50%? 
NR Yes Yes NR NR Yes Yes NR NR 
4. Were all the subjects selected or recruited from the 
same or similar populations (including the same time 
period)? Were inclusion and exclusion criteria for 
being in the study prespecified and applied uniformly 
to all participants? 
Yes Yes NR No No Yes No No NR 
5. Was a sample size justification, power description, 
or variance and effect estimates provided? 
Yes NR No No Yes Yes No No No 
6. For the analyses in this paper, were the exposure(s) 
of interest measured prior to the outcome(s) being 
measured? 
NA NA NA NA NA NA NA NA NA 
7. Was the timeframe sufficient so that one could 
reasonably expect to see an association between 
exposure and outcome if it existed? 
Yes Yes Yes Yes CD Yes Yes Yes Yes 
8. For exposures that can vary in amount or level, did 
the study examine different levels of the exposure as 
related to the outcome (e.g., categories of exposure, or 
exposure measured as continuous variable)? 
NA NA NA NA NA NA NA NA NA 
9. Were the exposure measures (independent variables) 
clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
NA NA NA NA NA NA NA NA NA 
10. Was the exposure(s) assessed more than once over 
time? 
NA NA NA NA NA NA NA NA NA 
32





11. Were the outcome measures (dependent variables) 
clearly defined, valid, reliable, and implemented 
consistently across all study participants? 
Yes Yes NR Yes Yes Yes Yes Yes CD 
12. Were the outcome assessors blinded to the 
exposure status of participants? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
13. Was loss to follow-up after baseline 20% or less? NA NA NA NA NA NA NA NA NA 
14. Were key potential confounding variables 
measured and adjusted statistically for their impact on 
the relationship between exposure(s) and outcome(s)? 
No Yes No Yes No No Yes NR Yes 
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Supplementary file 3. Quality Assessment of the included studies continued… 
Criteria Fisher Gagneux-
Brunon 
Graffigna Guidry Goldman Harapan Kabamba Lazarus Kreps 
1. Was the research question or objective in 
this paper clearly stated? 
Yes Yes Yes Yes Yes Yes Yes No Yes 
2. Was the study population clearly specified 
and defined? 
Yes Yes Yes Yes No No Yes No Yes 
3. Was the participation rate of eligible 
persons at least 50%? 
Yes NR NR NR NR NR NR NR Yes 
4. Were all the subjects selected or recruited 
from the same or similar populations 
(including the same time period)? Were 
inclusion and exclusion criteria for being in 
the study prespecified and applied uniformly 
to all participants? 
Yes Yes Yes Yes No Yes Yes No Yes 
5. Was a sample size justification, power 
description, or variance and effect estimates 
provided? 
No No No No No Yes No No Yes 
6. For the analyses in this paper, were the 
exposure(s) of interest measured prior to the 
outcome(s) being measured? 
Yes NA NA NA NA NA NA NA NA 
7. Was the timeframe sufficient so that one 
could reasonably expect to see an association 
between exposure and outcome if it existed? 
Yes Yes CD Yes Yes Yes Yes Yes Yes 
8. For exposures that can vary in amount or 
level, did the study examine different levels 
of the exposure as related to the outcome 
(e.g., categories of exposure, or exposure 
measured as continuous variable)? 
NA NA NA NA NA NA NA NA NA 
9. Were the exposure measures (independent 
variables) clearly defined, valid, reliable, and 
implemented consistently across all study 
participants? 
NA NA NA NA NA NA NA NA NA 
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10. Was the exposure(s) assessed more than 
once over time? 
NA NA NA NA NA NA NA NA NA 
11. Were the outcome measures (dependent 
variables) clearly defined, valid, reliable, and 
implemented consistently across all study 
participants? 
Yes Yes Yes Yes Yes Yes No Yes Yes 
12. Were the outcome assessors blinded to 
the exposure status of participants? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
13. Was loss to follow-up after baseline 20% 
or less? 
NA NA NA NA NA NA NA NA NA 
14. Were key potential confounding variables 
measured and adjusted statistically for their 
impact on the relationship between 
exposure(s) and outcome(s)? 
Yes No No Yes No Yes No Yes Yes 
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Supplementary file 3. Quality Assessment of the included studies continued… 
Criteria Malik Muqattash Neumann-
Bohme 
Palamenghi Papagiannis Pogue Reiter Reuben 
1. Was the research question or objective in this 
paper clearly stated? 
Yes Yes Yes Yes Yes Yes Yes Yes 
2. Was the study population clearly specified and 
defined? 
Yes No NR Yes Yes Yes Yes Yes 
3. Was the participation rate of eligible persons 
at least 50%? 
NR NR Yes NR Yes NR NR NR 
4. Were all the subjects selected or recruited 
from the same or similar populations (including 
the same time period)? Were inclusion and 
exclusion criteria for being in the study 
prespecified and applied uniformly to all 
participants? 
Yes No NR Yes Yes Yes Yes No 
5. Was a sample size justification, power 
description, or variance and effect estimates 
provided? 
Yes No Yes No No No No No 
6. For the analyses in this paper, were the 
exposure(s) of interest measured prior to the 
outcome(s) being measured? 
NA NA NA NA NA NA NA NA 
7. Was the timeframe sufficient so that one could 
reasonably expect to see an association between 
exposure and outcome if it existed? 
Yes Yes Yes Yes No Yes Yes Yes 
8. For exposures that can vary in amount or 
level, did the study examine different levels of 
the exposure as related to the outcome (e.g., 
categories of exposure, or exposure measured as 
continuous variable)? 
NA NA NA NA NA NA NA NA 
9. Were the exposure measures (independent 
variables) clearly defined, valid, reliable, and 
implemented consistently across all study 
participants? 
NA NA NA NA NA NA NA NA 
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10. Was the exposure(s) assessed more than once 
over time? 
NA NA NA NA NA NA NA NA 
11. Were the outcome measures (dependent 
variables) clearly defined, valid, reliable, and 
implemented consistently across all study 
participants? 
Yes No CD No No Yes Yes Yes 
12. Were the outcome assessors blinded to the 
exposure status of participants? 
Yes Yes Yes Yes Yes Yes Yes Yes 
13. Was loss to follow-up after baseline 20% or 
less? 
NA NA NA NA NA NA NA NA 
14. Were key potential confounding variables 
measured and adjusted statistically for their 
impact on the relationship between exposure(s) 
and outcome(s)? 
Yes No No CD No Yes Yes Yes 
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Supplementary file 3. Quality Assessment of the included studies continued… 





1. Was the research question or objective in this 
paper clearly stated? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
2. Was the study population clearly specified 
and defined? 
Yes Yes No Yes Yes Yes Yes Yes No 
3. Was the participation rate of eligible persons 
at least 50%? 
Yes NR NR Yes Yes Yes Yes NR NR 
4. Were all the subjects selected or recruited 
from the same or similar populations (including 
the same time period)? Were inclusion and 
exclusion criteria for being in the study 
prespecified and applied uniformly to all 
participants? 
Yes Yes No Yes Yes Yes Yes Yes No 
5. Was a sample size justification, power 
description, or variance and effect estimates 
provided? 
Yes No No No No No No No No 
6. For the analyses in this paper, were the 
exposure(s) of interest measured prior to the 
outcome(s) being measured? 
NA NA NA NA NA NA NA NA NA 
7. Was the timeframe sufficient so that one 
could reasonably expect to see an association 
between exposure and outcome if it existed? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
8. For exposures that can vary in amount or 
level, did the study examine different levels of 
the exposure as related to the outcome (e.g., 
categories of exposure, or exposure measured as 
continuous variable)? 
NA NA NA NA NA NA NA NA NA 
9. Were the exposure measures (independent 
variables) clearly defined, valid, reliable, and 
implemented consistently across all study 
participants? 
NA NA NA NA NA NA NA NA NA 
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10. Was the exposure(s) assessed more than 
once over time? 
NA NA NA NA NA NA NA NA NA 
11. Were the outcome measures (dependent 
variables) clearly defined, valid, reliable, and 
implemented consistently across all study 
participants? 
Yes Yes No CD Yes No No Yes Yes 
12. Were the outcome assessors blinded to the 
exposure status of participants? 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
13. Was loss to follow-up after baseline 20% or 
less? 
NA NA NA NA NA NA NA NA NA 
14. Were key potential confounding variables 
measured and adjusted statistically for their 
impact on the relationship between exposure(s) 
and outcome(s)? 
Yes Yes No Yes Yes No No No No 
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Supplementary file 4. List of excluded studies following full text review 
# Author (year) Title Reason for exclusion 
1 Al-Hajri (2020) Willingness of parents to vaccinate their children 
against influenza and the novel coronavirus disease-
2019 
The study did not provide enough data that could be 
extracted and analyzed as it was a letter to the editor, 
highlighting only their main findings 
2 The Coconel 
group 
A future vaccination campaign against COVID-19 at 
risk of vaccine hesitancy and politicisation 
The study did not provide enough data that could be 
extracted and analyzed as it was a published comment, 
highlighting only their main findings 
3 Daly (2020) Willingness to vaccinate against COVID-19 in the 
US: Longitudinal evidence from a nationally 
representative sample of adults from April–October 
2020 
The study was a preprint and had not yet been peer-
reviewed, so changes to their findings from this study 




Factors associated with parents' willingness to enroll 
their children in trials for COVID-19 vaccination. 
The study was focused on the willingness to enroll in 
clinical trials for covid-19 vaccination rather than if 
they wanted to get the vaccine once it becomes 
available 
5 Harapan (2020) Willingness-to-pay for a COVID-19 vaccine and its 
associated determinants in Indonesia 
The study was focused on participants’ willingness to 
pay for a vaccine at different vaccine costs but did not 
provide particular enablers or barriers to uptake 
6 Qiao (2020) Risk exposures, risk perceptions, negative attitudes 
toward general vaccination, and COVID-19 vaccine 
acceptance among college students in South Carolina 
The study was a preprint and had not yet been peer-
reviewed, so changes to heir findings from this study 
once published could affect the overall results from 
our review 
7 Sun (2020) Interest in COVID-19 vaccine trials participation 
among young adults in China: Willingness, reasons 
for hesitancy, and demographic and psychosocial 
determinants 
The study was focused on the willingness to enroll in 
clinical trials for covid-19 vaccination rather than if 
they wanted to get the vaccine once it becomes 
available. The study is also a preprint 
8 Thorneloe 
(2020) 
Willingness to receive a COVID-19 vaccine among 
adults at high-risk of COVID-19: a UK-wide survey 
The study was a preprint and had not yet been peer-
reviewed, so changes to their findings from this study 



















estimate (95% CI) 
Within-stratum  





Sample size ≥1000 19 0.71 (0.66 – 0.76) <0.001 
(99.27%) 
0.079 





High 19 0.70 (0.65 – 0.75) <0.001 
(98.94%) 
0.845 
 Low 12 0.73 (0.60 – 0.83) <0.001 
(99.63%) 
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Supplementary file 6. Pooled Vaccine Acceptance rate according to region of study 
 
 
The dashed line on the Forest plot represents the overall pooled estimate. The grey squares 
and horizontal lines represent the odds ratios of each study and their 95% confidence intervals. 
The size of the grey square represents the weight contributed by each study in the meta-
analysis. The diamond represents the pooled odds ratio and its 95% confidence intervals. 
 
 
Heterogeneity between groups: p = 0.000







Subtotal  (I^2 = .%, p = .)






























Subtotal  (I^2 = 99.63%, p = 0.00)
Salali - study 2
Salali - study 1























































































































.5 .6 .7 .8 .9 1
42
Advances in Clinical Medical Research and Healthcare Delivery, Vol. 1 [2021], Iss. 3, Art. 1
https://scholar.rochesterregional.org/advances/vol1/iss3/1
DOI: 10.53785/2769-2779.1076
